| Literature DB >> 26046436 |
Stuart L Schreiber1, Joanne D Kotz2, Min Li3, Jeffrey Aubé4, Christopher P Austin5, John C Reed6, Hugh Rosen7, E Lucile White8, Larry A Sklar9, Craig W Lindsley10, Benjamin R Alexander11, Joshua A Bittker12, Paul A Clemons13, Andrea de Souza14, Michael A Foley14, Michelle Palmer14, Alykhan F Shamji13, Mathias J Wawer13, Owen McManus3, Meng Wu3, Beiyan Zou3, Haibo Yu3, Jennifer E Golden15, Frank J Schoenen15, Anton Simeonov5, Ajit Jadhav5, Michael R Jackson6, Anthony B Pinkerton6, Thomas D Y Chung6, Patrick R Griffin16, Benjamin F Cravatt7, Peter S Hodder17, William R Roush18, Edward Roberts17, Dong-Hoon Chung8, Colleen B Jonsson8, James W Noah8, William E Severson8, Subramaniam Ananthan8, Bruce Edwards9, Tudor I Oprea19, P Jeffrey Conn10, Corey R Hopkins10, Michael R Wood10, Shaun R Stauffer20, Kyle A Emmitte10.
Abstract
Small-molecule probes can illuminate biological processes and aid in the assessment of emerging therapeutic targets by perturbing biological systems in a manner distinct from other experimental approaches. Despite the tremendous promise of chemical tools for investigating biology and disease, small-molecule probes were unavailable for most targets and pathways as recently as a decade ago. In 2005, the NIH launched the decade-long Molecular Libraries Program with the intent of innovating in and broadening access to small-molecule science. This Perspective describes how novel small-molecule probes identified through the program are enabling the exploration of biological pathways and therapeutic hypotheses not otherwise testable. These experiences illustrate how small-molecule probes can help bridge the chasm between biological research and the development of medicines but also highlight the need to innovate the science of therapeutic discovery.Entities:
Mesh：
Substances：
Year: 2015 PMID： 26046436 PMCID： PMC4564295 DOI： 10.1016/j.cell.2015.05.023
Source DB: PubMed Journal: Cell ISSN： 0092-8674 Impact factor: 41.582